Intelligent Bio Solutions to Present PK Study Data at Association for Diagnostics and Laboratory Medicine 2025 Clinical Lab Expo
Intelligent Bio Solutions (Nasdaq: INBS) announced it will present Pharmacokinetic (PK) study data at the ADLM 2025 Clinical Lab Expo in Chicago from July 27-31. The study demonstrates that their Intelligent Fingerprinting Drug Screening System effectively detects codeine through fingerprint sweat analysis, with results closely matching blood-based testing at a 95% confidence level.
The company's non-invasive drug screening technology is currently used across 450 accounts in 24 countries, serving various sectors including construction, transportation, and manufacturing. The presentation will be delivered by Daniel Brown, Head of Clinical Affairs, in the ADLM Poster Hall, featuring over 700 presentations.
Intelligent Bio Solutions (Nasdaq: INBS) ha annunciato che presenterà i dati di uno studio farmacocinetico (PK) al ADLM 2025 Clinical Lab Expo a Chicago, dal 27 al 31 luglio. Lo studio dimostra che il loro Sistema Intelligente di Screening dei Farmaci tramite Impronte Digitali rileva efficacemente la codeina attraverso l'analisi del sudore delle impronte digitali, con risultati che corrispondono strettamente ai test ematici con un livello di confidenza del 95%.
La tecnologia di screening dei farmaci non invasiva dell'azienda è attualmente utilizzata in 450 account in 24 paesi, servendo diversi settori tra cui costruzioni, trasporti e manifatturiero. La presentazione sarà tenuta da Daniel Brown, Responsabile degli Affari Clinici, nella ADLM Poster Hall, che ospita oltre 700 presentazioni.
Intelligent Bio Solutions (Nasdaq: INBS) anunció que presentará datos de un estudio farmacocinético (PK) en la ADLM 2025 Clinical Lab Expo en Chicago, del 27 al 31 de julio. El estudio demuestra que su Sistema Inteligente de Detección de Drogas mediante Huellas Dactilares detecta eficazmente la codeína a través del análisis del sudor de las huellas, con resultados que coinciden estrechamente con las pruebas sanguíneas con un nivel de confianza del 95%.
La tecnología de detección de drogas no invasiva de la compañía se utiliza actualmente en 450 cuentas en 24 países, atendiendo a diversos sectores como construcción, transporte y manufactura. La presentación será realizada por Daniel Brown, Jefe de Asuntos Clínicos, en el ADLM Poster Hall, que contará con más de 700 presentaciones.
Intelligent Bio Solutions (나스닥: INBS)는 7월 27일부터 31일까지 시카고에서 열리는 ADLM 2025 Clinical Lab Expo에서 약동학(PK) 연구 데이터를 발표할 예정입니다. 본 연구는 지문 땀 분석을 통해 코데인을 효과적으로 감지하는 Intelligent Fingerprinting Drug Screening System이 혈액 검사 결과와 95% 신뢰 수준에서 거의 일치함을 보여줍니다.
이 회사의 비침습적 약물 검사 기술은 현재 24개국 450개 계정에서 건설, 운송, 제조업 등 다양한 분야에 사용되고 있습니다. 발표는 임상 업무 책임자인 다니엘 브라운이 ADLM 포스터 홀에서 진행하며, 700개 이상의 발표가 예정되어 있습니다.
Intelligent Bio Solutions (Nasdaq : INBS) a annoncé qu'elle présenterait des données d'une étude pharmacocinétique (PK) lors du ADLM 2025 Clinical Lab Expo à Chicago, du 27 au 31 juillet. L'étude démontre que leur Système Intelligent de Dépistage des Drogues par Empreintes Digitales détecte efficacement la codéine via l'analyse de la sueur des empreintes digitales, avec des résultats très proches des tests sanguins, avec un niveau de confiance de 95 %.
La technologie de dépistage non invasive de l'entreprise est actuellement utilisée dans 450 comptes dans 24 pays, desservant divers secteurs tels que la construction, le transport et la fabrication. La présentation sera assurée par Daniel Brown, responsable des affaires cliniques, dans le hall des posters ADLM, qui compte plus de 700 présentations.
Intelligent Bio Solutions (Nasdaq: INBS) gab bekannt, dass es Pharmakokinetik(PK)-Studienergebnisse auf der ADLM 2025 Clinical Lab Expo in Chicago vom 27. bis 31. Juli vorstellen wird. Die Studie zeigt, dass ihr Intelligentes Fingerabdruck-Drogenscreening-System Codein effektiv durch Schweißanalyse der Fingerabdrücke erkennt, mit Ergebnissen, die den blutbasierten Tests auf einem 95%-Konfidenzniveau sehr nahekommen.
Die nicht-invasive Drogenscreening-Technologie des Unternehmens wird derzeit in 450 Accounts in 24 Ländern eingesetzt und bedient verschiedene Branchen wie Bau, Transport und Fertigung. Die Präsentation wird von Daniel Brown, Leiter der Klinischen Angelegenheiten, in der ADLM Poster Hall gehalten, die über 700 Präsentationen umfasst.
- None.
- None.
Data shows excretion of codeine in fingerprint sweat
INBS’ System is viable option for non-invasive diagnostic testing
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing and screening solutions, today announced that it will present its Pharmacokinetic (“PK”) study data at the Association for Diagnostics and Laboratory Medicine (“ADLM”) 2025 Clinical Lab Expo, taking place July 27–31 in Chicago, Illinois.
The PK study collected human fingerprint sweat specimens for laboratory analysis and used INBS’s Intelligent Fingerprinting Drug Screening System (the “System”), a portable, non-invasive system that screens for drugs of abuse via sweat from the fingertips. Study data showed that fingerprint sweat mirrors the rate and extent of codeine found in blood and saliva, making it a strong indicator of codeine ingestion. Statistical comparisons made at the
“ADLM is an important gathering for laboratory medicine professionals, and we’re pleased to share data showing that fingerprint sweat specimens reflect the recent ingestion of codeine. This reinforces that our system of fingerprint sweat testing is a viable option for non-invasive diagnostic testing,” said Daniel Brown, Head of Clinical Affairs at Intelligent Bio Solutions. “We see growing demand for innovative drug screening approaches that are simple to administer, minimize biohazard risks, and offer reliable, rapid results.”
Daniel Brown will represent the Company at the event, participating in the ADLM Poster Hall, an open-access forum featuring more than 700 presentations spanning the breadth of laboratory medicine. He will present the background, methodology and findings of the Company’s recent PK Study and will be available during unopposed discussion periods to engage directly with attendees.
ADLM 2025 is the world’s premier global laboratory medicine exposition, bringing together international leaders, scientists, and innovators for a week of presentations, workshops, and networking. With over 300 expert speakers, more than 250 educational sessions, and 200 plus product categories, the event offers a platform to explore advances in diagnostic technologies and clinical laboratory innovation.
ADLM 2025 is held in partnership with the Canadian Society of Clinical Chemists (CSCC) and covers a broad spectrum of topics, from AI and mass spectrometry to disruptive technologies and diagnostic advancements. Attendees are invited to learn more about INBS’s technology, explore its real-world applications, and connect with the Company’s representatives to discuss collaboration and adoption opportunities.
The Company’s Drug Screening System is designed to support accurate, dignified, and efficient testing in workplace, treatment, and justice settings. With more than 450 accounts across 24 countries, INBS continues to expand its reach across numerous sectors, including construction, transportation, engineering, mining, and manufacturing. The Company’s participation in ADLM 2025 highlights its commitment to innovation and growing relevance within laboratory and diagnostic testing communities.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.
For more information, visit: http://www.ibs.inc
Forward-Looking Statements:
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact:
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
Investor & Media Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa
FAQ
When and where will Intelligent Bio Solutions (INBS) present its PK study data in 2025?
What are the key findings of INBS's Pharmacokinetic study for drug screening?
How many accounts does INBS's Drug Screening System currently serve?
What are the main advantages of INBS's fingerprint sweat testing system?
Who will represent INBS at the ADLM 2025 Clinical Lab Expo?
